AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2)

BACKGROUND: Neurogenic detrusor overactivity incontinence (NDOI) is often inadequately managed with oral therapy. OBJECTIVE: To assess efficacy and safety of abobotulinumtoxinA (aboBoNT‐A; Dysport®; Ipsen Ltd.) according to etiology of NDOI. DESIGN, SETTING, AND PARTICIPANTS: Two phase III, randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Denys, Pierre, Castaño Botero, Juan Carlos, Vita Nunes, Ricardo Luis, Wachs, Barton, Mendes Gomes, Cristiano, Krivoborodov, Grigory, Tu, Le Mai, Del‐Popolo, Giulio, Thompson, Catherine, Vilain, Claire, Volteau, Magali, Kennelly, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092111/
https://www.ncbi.nlm.nih.gov/pubmed/36321799
http://dx.doi.org/10.1002/nau.25062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092111/
https://www.ncbi.nlm.nih.gov/pubmed/36321799
http://dx.doi.org/10.1002/nau.25062

Ejemplares similares